Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Revenue : ¥1,154 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Chengdu Easton Biopharmaceuticals Co Revenue?

Chengdu Easton Biopharmaceuticals Co's revenue for the three months ended in Mar. 2024 was ¥315 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,154 Mil. Chengdu Easton Biopharmaceuticals Co's Revenue per Share for the three months ended in Mar. 2024 was ¥2.65. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥9.64.

Warning Sign:

Chengdu Easton Biopharmaceuticals Co Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Chengdu Easton Biopharmaceuticals Co was -1.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 0.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Chengdu Easton Biopharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 39.30% per year. The lowest was -2.70% per year. And the median was 10.20% per year.

Chengdu Easton Biopharmaceuticals Co Revenue Historical Data

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Easton Biopharmaceuticals Co Revenue Chart

Chengdu Easton Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue

Get a 7-Day Free Trial

947.24

921.92

1,022.94

1,170.51

1,117.12

Chengdu Easton Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Revenue	Get a 7-Day Free Trial															277.85	277.51	294.42	267.34	314.99

Competitive Comparison of Chengdu Easton Biopharmaceuticals Co's Revenue

For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chengdu Easton Biopharmaceuticals Co's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Revenue distribution charts can be found below:

* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Revenue falls into.

Chengdu Easton Biopharmaceuticals Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,154 Mil.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Chengdu Easton Biopharmaceuticals Co Revenue Related Terms

Thank you for viewing the detailed overview of Chengdu Easton Biopharmaceuticals Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Easton Biopharmaceuticals Co Ltd (SHSE:688513) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731

Website

http://www.eastonpharma.cn

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Headlines

No Headlines